Analyst Activity – HC Wainwright Reiterates Buy on Asterias Biotherapeutics (NYSE:AST)

Analyst Ratings For Asterias Biotherapeutics (NYSE:AST)

Story continues below

Today, HC Wainwright reiterated its Buy rating on Asterias Biotherapeutics (NYSE:AST) with a price target of $12.00.

There are 2 buy ratings on the stock.

The current consensus rating on Asterias Biotherapeutics (NYSE:AST) is Buy (Score: 3.00) with a consensus target price of $12.00 per share, a potential 233.33% upside.

Some recent analyst ratings include

  • 10/2/2017-HC Wainwright Reiterated Rating of Buy.
  • 4/4/2017-Laidlaw initiated coverage with a Buy rating.


    Recent Trading Activity for Asterias Biotherapeutics (NYSE:AST)
    Shares of Asterias Biotherapeutics closed the previous trading session at with shares trading hands.

    An ad to help with our costs